Should You Buy Pfizer While It’s Under $30?

Date:

Share post:


It might not pay off immediately, but it could, eventually.

Trading at a bit under $25 apiece, Pfizer‘s (PFE 0.36%) shares appear tentatively cheap. However, the pharmaceutical giant reached these levels because it has faced significant headwinds, resulting in a poor stock market performance over the past three years.

Yet, what is the outlook for the struggling giant from here? Is Pfizer worth investing in at current levels?

Image source: Getty Images.

Slowly engineering a comeback

Pfizer’s revenue and earnings have been inconsistent over the past few years. To make matters worse, the drugmaker will encounter important patent cliffs within a few years, including that of Eliquis, an anticoagulant and one of its best-selling drugs. Even so, the company has been gradually earning new approvals, some of which should have a meaningful impact on its financial results as label expansions are secured.

Further, Pfizer has doubled down on acquisitions, which has helped it improve its pipeline. The company now has a comprehensive list of candidates across multiple therapeutic areas, with a particular focus on cancer. It also boasts a promising candidate for weight loss. Pfizer should launch several new products that will bolster its lineup through the end of the decade.

Pfizer Stock Quote

Today’s Change

(-0.36%) $-0.09

Current Price

$24.90

Even more reasons to buy

Purchasing shares of top companies when they are down is a great way to earn excellent returns over the long run. Pfizer is a top pick to consider, given that it has been making the right moves to overcome slow (or non-existent) revenue growth and patent cliffs. And there are even more reasons to consider the stock. Here are three.

First, Pfizer penned a deal with the Trump administration that will allow it to avoid tariffs for three years. Second, the company is a solid dividend payer. It has increased its payouts by 51.3% over the past decade, and boasts a juicy forward yield of 6.9%.

Lastly, Pfizer is trading at 8.5 times forward earnings, much lower than the 18.4 healthcare sector average. All these make for compelling reasons to buy the stock.

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related articles

CME vs. Morningstar: Which Financial Stock Is a Better Buy for 2027?

When choosing between exchange operators and data providers, do you prioritize massive profit margins or broad research...

Introduction to Management, chapter 1, part 1 Management: An Overview

Introduction to Management, chapter 1, part 1 Management: An Overview learn the following topics in this part; Define Management Explain the...

Why One Better Rental Beats Several Cheap Ones (Rookie Reply)

Is a cheap rental really the safest way to start, or does it just trade one risk...

Turkish Airlines Chase Offer: Spend $1,000 and Get $50 Back

Turkish Airlines Chase Offer Chase has a new targeted offer for Turkish Airlines that can save you money...